Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fujimasa Tada

Showing results (61-70 of 117) with videos related to

Pageof 12
Sort By:
Journal of Gastroenterology and Hepatology|April 18, 2024
Changes in characteristics of gastroenterology center inpatients in Japan because of rapidly aging societyYoshiko Fukunishi, Atsushi Hiraoka, Fujimasa Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 11, 2026
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular CarcinomaKazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.
Journal of Gastroenterology|March 7, 2025
Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide surveyTakao Miwa, Mio Tsuruoka, Hajime Ueda, et al.
Cancer Medicine|December 9, 2022
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation studyToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Medicine|December 15, 2022
Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Oncology|December 1, 2022
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus BevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 6, 2023
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysisTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Journal of Gastroenterology and Hepatology|January 6, 2025
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk ModelsTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Journal of Gastroenterology and Hepatology|May 26, 2023
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Oncology|September 14, 2022
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Pageof 12

Showing results (61-70 of 117) with videos related to

Sort By:
Pageof 12
Journal of Gastroenterology and Hepatology|April 18, 2024
Changes in characteristics of gastroenterology center inpatients in Japan because of rapidly aging societyYoshiko Fukunishi, Atsushi Hiraoka, Fujimasa Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 11, 2026
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular CarcinomaKazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.
Journal of Gastroenterology|March 7, 2025
Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide surveyTakao Miwa, Mio Tsuruoka, Hajime Ueda, et al.
Cancer Medicine|December 9, 2022
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation studyToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Medicine|December 15, 2022
Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Oncology|December 1, 2022
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus BevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 6, 2023
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysisTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Journal of Gastroenterology and Hepatology|January 6, 2025
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk ModelsTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Journal of Gastroenterology and Hepatology|May 26, 2023
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Oncology|September 14, 2022
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Pageof 12